# PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)

> **NCT03658447** · PHASE1,PHASE2 · COMPLETED · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 37 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** 177Lu-PSMA

## Key facts

- **NCT ID:** NCT03658447
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-12
- **Primary completion:** 2022-12-22
- **Final completion:** 2022-12-22
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03658447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03658447, "PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03658447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*